Aethlon Medical, Inc. (AEMD) Receives FDA Clinical Protocol Approval of Ebola Treatment, Hemopurifier

January 2, 2015 12:41 PM

4 0

Aethlon Medical, Inc. (OTCBB: AEMD) announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier. In the treatment of viral pathogens, the Hemopurifier is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.

The approved Ebola treatment protocol allows for an investigational study to be conducted at up to 10 U.S. clinical sites, and up to 20 U.S. subjects may be enrolled to receive the treatment protocol. Patients who meet the enrollment criteria will receive a daily six to eight hour administration of ...

Read more

To category page